Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImmunGene Inc.

www.immungene.com

Latest From ImmunGene Inc.

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.

Deals Business Strategies

Start-Up Previews, January 2014

This Month's Profile Group, New Technologies Drive Growth In Orthopedic Extremities, features profiles of Cartiva, Conventus Orthopaedics, and Nextremity Solutions. Plus these Start-Ups Across Health Care: Arvinas, Flower Orthopedics, ImmunGene, and NeuroRecovery Technologies.

BioPharmaceutical Medical Device

ImmunGene Inc.

Interferon has proved helpful in treating many diseases, but its usefulness has always been limited by side effects that arise from the drug's inherent ability to stimulate the immune system. Start-up ImmunGene Inc. thinks it has figured out a way to engineer interferon so that it has little potency unless and until the protein binds to a tumor, only then displaying an active form of interferon capable of provoking inflammation and triggering cell death.

BioPharmaceutical

Start-Up Execs On The Move, December 2013

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ImmunGene Inc.
  • Senior Management
  • Sanjay Khare, PhD, Pres., CEO & Chmn.
    Iqbal S Grewal, PhD, CSO
    Linda Pullan, PhD, Consultant CBO
    Raj Sachdev, PhD, COO
  • Contact Info
  • ImmunGene Inc.
    Phone: (805) 496-6700
    558 St. Charles Dr.
    Ste. 200
    Thousand Oaks, CA 91360
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register